Evidence map›Paper›PMID 42693432›Full record

ReviewJournal of nanobiotechnology2026

Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.

Yun Wang, Yan Fan, Jing Zhang, Ning Sun, Kang Chen, Qasim Khan, Haishan Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yun Wang *Department of Anesthesiology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, Liaoning province, China.
Yan Fan *Department of Pediatrics, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Jing Zhang *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Ning SunDepartment of Emergency, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Kang ChenDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Qasim KhanUniversity of Calgary, Calgary, AB, T2N 1N4, Canada. qasim@agriphoton.com.
Haishan ZhangDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China. zhanghaishan99@sohu.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has transformed oncology, however, its clinical efficacy remains limited by immunosuppressive tumor microenvironments (TMEs), poor therapeutic delivery, systematic toxicity, treatment resistance. Chitosan, a biocompatible and biodegradable polysaccharide, has emerged as a versatile biomaterial capable of addressing these challenges through both intrinsics immunomodulatory activity and advanced drug-delivery functions. This review summarizs recent advances in chitosan-based biomaterials for cancer immunotherapy, highlighting their ability to activate innate and adaptive immune responses through pathways involving patterns recognition receptors, cyclic GMP-AMP synthase (cGAS)=simulator of interferon genes (STING) signaling, dendric cells (DCs)macrophages, natural killer (NK) cells and T lymphocytes. The design and application of chitosan-based nanoparticles and hydrogels as platformsfor delivering cytokines, nucleic acids, immune adjuvant, cancer vaccines and immune checkpoint therapeutics are discussed. Particular attention is given to their roles in TME remodeling, sustained local drug release, postsurgical immunotherapy, and combination approaches that integrate chemotherapy, radiotherapy (RT), phototherapy and immunotherapy. Emerging strategies, including stimuli-responsive systems, biomimetic formulations, and multifunctional nanoplatforms are also discussed. Finally, we discuss the current translational current translational challenges and future perspectives, emphasizing the potential of chitosan-based biomaterials to enhance antitumor immunity and improve clinical outcomes in cancer immunotherapy.

Indexed as

Biocompatible MaterialsChitosanDrug CarriersImmunotherapyNanoparticlesNeoplasmsTumor MicroenvironmentAnimalsDrug Delivery SystemsHumansHydrogelsBiocompatible MaterialsChitosanDrug CarriersHydrogelsCancer immunotherapyChitosan-based biomaterialsDrug deliveryImmunomodulationNanoparticlesNatural killer cellsTherapeutic platforms

Identifiers

PMID42693432
PMCPMC13540247

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.